Pexelizumab Explained

Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting and angioplasty,[1] among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.[2]

Current status

Alexion, the developer of pexelizumab, stopped development when the phase 3 trial indicated the heart-attack drug is no better than placebo.[3]

Notes and References

  1. Testa L, Van Gaal WJ, Bhindi R, Biondi-Zoccai GG, Abbate A, Agostoni P, Porto I, Andreotti F, Crea F, Banning AP . 6 . Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients . The Journal of Thoracic and Cardiovascular Surgery . 136 . 4 . 884–93 . October 2008 . 18954626 . 10.1016/j.jtcvs.2007.12.062 . free .
  2. Mathew JP, Shernan SK, White WD, Fitch JC, Chen JC, Bell L, Newman MF . Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery . Stroke . 35 . 10 . 2335–9 . October 2004 . 15331798 . 10.1161/01.STR.0000141938.00524.83 . free .
  3. Web site: Steve . Mitchell . vanc . 2 January 2007 . Analysis: Alexion's pexelizumab fails. United Press International .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Pexelizumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.